Market revenue in 2023 | USD 148.4 million |
Market revenue in 2030 | USD 203.8 million |
Growth rate | 4.6% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.89% in 2023. Horizon Databook has segmented the Spain attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
Currently, psychostimulants, such as methylphenidate & lisdexamfetamine, and nonstimulants, such as atomoxetine, are the official drugs approved for use in Spain. The Spanish guidelines from 2017 provide a comprehensive description of the evidence underlying the recommendations for medical treatment in children and adolescents with ADHD.
In adolescents and children aged 6 years and above, medication therapy is recommended when psychological & psychoeducational therapies have not been working or when the individual has chronic symptoms of ADHD. These guidelines state that methylphenidate, lisdexamfetamine, atomoxetine, and guanfacine are licensed for the treatment of ADHD in children and adolescents in Spain.
Atomoxetine is the only medication licensed for use in Spain for the treatment of adult ADHD patients. However, the osmotic-controlled release of methylphenidate and lisdexamfetamine may be continued into adulthood. In May 2023, the Community of Madrid was expected to implement the Protocol for the Care of People with Attention Deficit Hyperactivity Disorder (ADHD) in health centers.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into Spain attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account